Kylo-11 is an experimental yearly injection that turns down liver production of a genetically set particle tied to artery disease and aortic valve thickening. 225 mg or higher kept levels far below baseline for about a year in healthy young adults, with no drug-related unwanted effects. Heart attacks or healthy lifespan not yet shown. Research studies only. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Lp(a) | <75 nmol/L; many longevity clinics aim still lower | Confirms lowering and durability |
| Apolipoprotein B (apoB) | <60–80 mg/dL | Tracks residual plaque-forming particles after Lp(a) falls |
| LDL-C | <70 mg/dL (<55 mg/dL if very high risk) | Background cholesterol risk still matters |
| ALT / AST | ALT <25 U/L (women) or <33 U/L (men) | Liver-cell delivery of the drug |
| Creatine kinase (CK) | Change from personal baseline; conventional ~30–200 U/L | Caught the phase 1 grade 3 signal |
| HbA1c | <5.4% | Theoretical diabetes question at very low Lp(a) |
| Fasting glucose | 70–90 mg/dL | Same metabolic watch item |
| eGFR | ≥90 mL/min/1.73 m² | Baseline kidney status in older adults |
| hs-CRP | <0.5–1.0 mg/L | Residual inflammatory context |
Cadence: A draw at 4 weeks, 12 weeks, 26 weeks, and 12 months, then yearly if dosing continues, matching phase 2 windows of weeks 8–26 and 38–52; liver enzymes and CK on those visits